Am J Transplant, Volume 5, Suppl 3 Archives - Page 18 of 170 - ATC Abstracts

2015 American Transplant Congress
Phenotype of Renal Tubular Cell Death During Delayed Graft Function
S. Jain,¹ R. Plenter,¹ T. Nydam,¹ C. Ruller,¹ C. Edelstein,^1,2 A. Jani.^1,2
¹University of Colorado, Aurora, CO; ²Veterans Affairs Medical Center, Denver, CO.
Background: Delayed graft function (DGF) independently predicts reduced 5 yr kidney transplant survival. Treatments of DGF are lacking. Cold ischemia (CI) is a significant risk…
2015 American Transplant Congress
Calcineurin-Inhibitor Conversion to mTOR Inhibitor in Renal Transplant Recipients Leads to Worse Long Term Clinical Outcomes
A. Alvarado,¹ A. Shetty,¹ O. Traitanon,¹ J. Leventhal,¹ V. Mas,² D. Chhabra,³ J. Matthews,¹ L. Gallon.¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²University of Virgina, Charlottesville, Va; ³Advocate Christ Medical Center, Chicago, IL.
We previously reported the short-term feasibility of Calcineurin-Inhibitor (CNI) elimination in kidney transplant recipients. We now report the long-term clinical impact on renal allograft function…
2015 American Transplant Congress
NFAT Regulated Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Recipients
V. Tatapudi, A. Webber, C. Leung, F. Vincenti.
Div. of Nephrology, Dept. of Medicine, University of California, San Francisco Medical Center, San Francisco, CA.
Purpose of Study:To demonstrate that profiling kidney transplant recipients (KTR) on Tacrolimus (Tac) based immunosuppression based on quantitative analysis of NFAT (nuclear factor of activated…
2015 American Transplant Congress
12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients
C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ I. Hauser,¹ P. Schenker,¹ D. Bäumer,² B. Nashan,¹ F. Thaiss.¹
¹Athena Study Group, Germany; ²Novartis, Pharma, Germany.
Background: Post-kidney transplant (KTx) long-term and full dose/standard calcineurin inhibitor (CNI) use is associated with an increased risk for malignancies, cardiovascular disease, and renal failure.…
2015 American Transplant Congress
The Clinical Outcome of Plasma Cell-Rich Rejection of Kidney Allograft
J. Hasegawa,¹ K. Honda,² S. Wakai,¹ H. Shirakawa,³ M. Okumi,³ K. Omoto,³ H. Ishida,³ K. Tanabe.³
¹Nephrology, Ohkubo Hospital, Tokyo, Japan; ²Pathology, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background: Plasma cell-rich rejection (PCRR) is a rare type of allograft rejection characterized by the presence of mature plasma cells. This type of rejection has…
2015 American Transplant Congress
SBRT(Stereotactic Body Radiotherapy) to Bridge or Down-Size HCC for Liver Transplantation
N. Thai,¹ K. Tom,¹ M. Szramowski,¹ P. Abrams,¹ J. Oliva,³ D. Monga,⁴ M. Raj,⁴ D. Parda,² A. Kirichenko.²
¹Transplant Surgery, Allegheny Health Network, Pittsburgh, PA; ²Radiation Oncology, Allegheny Health Network, Pittsburgh, PA; ³Hepatology, Allegheny Health Network, Pittsburgh, PA; ⁴Medical Oncology, Allegheny Health Network, Pittsburgh, PA.
Twenty seven (27) pts with HCC and cirrhosis have been treated with SBRT with intent for liver transplantation since 2010 at Allegheny Health Network. Nineteen…
2015 American Transplant Congress
Severe Sarcopenia and Increased Fat Stores in Pediatric Patients With Liver, Kidney and Intestine Failure
W. Bush, C. Miller, C. Kubal, J. Fridell, A. Tector, R. Mangus.
Transplant Division, Dept of Surgery, Indiana University School of Medicine, Indianapolis, IN.
Background: Recent research suggests that measures of frailty, such as nutrition status, may be important predictors of surgical and transplant outcomes. The objectively calculated degree…
2015 American Transplant Congress
Pubertal Development in Pediatric Kidney Transplant Patients Receiving Everolimus Or Conventional Immunosuppression
L. Pape,¹ T. Ahlenstiel-Grunow,¹ A. Zapf,² M. Mynarek,³ J. Förster.¹
¹Pediatric Nephrology, Hannover Medical School, Hannover, NDS, Germany; ²Medical Statistics, University Medical Center Göttingen, Göttingen, NDS, Germany; ³Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
TOR inhibitors (mTORi) have been discussed to eventually influence pubertal development after pediatric kidney transplantation (Tx).This is the first trial to compare pubertal development in…
2015 American Transplant Congress
Cancer Mortality Among Recipients of Solid Organ Transplant in Ontario
S. Acuna,^1,2,3 K. Fernandes,⁴ C. Daly,^2,3 L. Hicks,³ R. Sutradhar,^1,4 S. Kim,^1,4 N. Baxter.^1,2,3,4
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ³Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Purpose: Solid organ transplantation recipients (SOTR) have a higher risk of some cancers than the general population, but are also at high risk of mortality…
2015 American Transplant Congress
Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias
V. Domínguez-Pimentel,¹ F. Fortich-Barrios,¹ O. Siverio-Morales,¹ E. Martín-Izquierdo,¹ A. Jarque-López,¹ N. Del Castillo-Rodríguez,¹ J. García,¹ P. Ríos,² M. Macía.¹
¹Division of Nephrology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain; ²Division of Hematology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
INTRODUCTION:The plasma cell dyscrasias (PCD) include a number of entities such as multiple myeloma (MM), primary amyloidosis (AL) and Monoclonal immunoglobulin deposition disease (MIDD). Hematopoietic…